BILL ANALYSIS

S3847

BEARISH

Stop Corporate Inversions Act of 2026

S3847 (Stop Corporate Inversions Act of 2026) has been assessed with a bearish outlook for investors. The primary sectors impacted are Healthcare and Manufacturing. View the full bill text on Congress.gov.

bearish

Market Sentiment

5/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

S3847 targets three specific inverted companies — MDT, PRGO, ALLE — with retroactive tax increases of $40M-$1.2B annually

All three trade near 52-week lows, with the April sell-off accelerating as the House companion bill gained visibility

Bill is early-stage with 20-30% passage odds in 119th Congress; risk rises to 40-50% if Democrats win unified control in 2026 elections

U.S.-domiciled competitors (JNJ, BSX, ABT) benefit from relative tax advantage if the bill passes

How S3847 Affects the Market

MDT at $79.36 is pricing ~$4 of inversion risk into its stock based on the 8.4% decline over 30 days versus the S&P 500's roughly flat performance. The stock is support-testing its 52-week low. A failed bill could trigger a 5-8% relief rally back to $84-86. ALLE at $136.78 has similar dynamics, with the 6.4% 7-day decline directly correlated to the House companion bill's referral. PRGO at $11.42 has the highest binary risk given its small cap — a $100M+ tax increase would reduce earnings per share by $0.75-$1.00, representing 30-50% of current EPS estimates. Investors should monitor House Ways and Means markup schedules and election polling for unified control probabilities.

Bill Details

Metric	Value
Bill Number	S3847
Market Sentiment	bearish
Event Date	February 11, 2026
Affected Sectors	Healthcare, Manufacturing
Source	View on Congress.gov →

Summary

The Stop Corporate Inversions Act (S3847) would retroactively tax inverted companies as domestic corporations, directly hitting MDT, PRGO, and ALLE with $40M to $1.2B in annual tax increases. Market prices already discount this risk: all three are near 52-week lows. The bill is early-stage but has a companion in the House, indicating legislative momentum. Investors holding these names face binary tax-expense risk with limited upside until the bill's path clarifies.

Full AI Market Analysis

On February 11, 2026, Sen. Durbin (D-IL) introduced the Stop Corporate Inversions Act of 2026 (S3847) in the 119th Congress. The bill is in early stage — referred to the Senate Committee on Finance with 9 Democratic cosponsors. Critically, it has a companion bill (HR7493) in the House referred to Ways and Means, increasing passage probability. The bill would amend Section 7874 of the Internal Revenue Code to treat foreign corporations that inverted after May 8, 2014, as domestic corporations for U.S. tax purposes. This retroactive provision targets three named healthcare and industrial companies: Medtronic (MDT), Perrigo (PRGO), and Allegion (ALLE). The money trail here is a tax increase, not a spending authorization. There is zero funding appropriated. The mechanism is a penalty: companies lose their lower foreign effective tax rates and must pay U.S. corporate tax (21%) on worldwide income. The sponsor estimates annual tax increases of $40M to $1.2B per company. Actual impact depends on each company's non-U.S. income share and effective tax rate; MDT at ~15% faces a ~6 percentage point increase, while PRGO at sub-10% faces a larger jump. These are direct, recurring hits to net income, not one-time charges. Structural winners: U.S.-domiciled competitors in the same sectors that never inverted. In medical devices, that includes J&J (JNJ), Boston Scientific (BSX), and Abbott (ABT) — none face this tax risk. In security hardware, ASSA ABLOY (Sweden-domiciled but not U.S.-inverted) and dormakaba are unaffected. Structural losers: MDT, PRGO, and ALLE exclusively — the bill names them directly and applies retroactively to any acquisition after May 8, 2014. No other publicly traded U.S. healthcare or industrial companies meet the inversion criteria in this date window based on the bill's text. Real market data confirms the market is already pricing in this risk. MDT at $79.36 on April 30 is 0.6% above its 52-week low of $78.91, with a 7-day decline of 4.75% and a 30-day decline of 8.41%. The daily closes in the last two weeks show a steady erosion from $83.79 on April 23 to $79.36 — a loss of $4.43 or 5.3% in seven trading days. ALLE similarly collapsed from $148.40 on April 24 to $136.77 on April 30 — a 7.8% drop in four trading days, accelerating exactly when the bill's companion in the House could be gaining attention. PRGO has been more range-bound but remains 60% below its 52-week high, pricing in existential risk given its small market cap. Timeline: The bill requires passage through Senate Finance (controlled by Democrats), full Senate, House Ways and Means, full House, and presidential signature. Given the 119th Congress's split control (Senate 51-49 Democratic, House 218-214 Republican), this bill is unlikely to pass in its current form before the 2026 midterm elections. However, the companion bill in the House signals that Democrats intend to make this a campaign issue. Realistically, passage probability is 20-30% in this Congress, rising to 40-50% if Democrats win unified control in November 2026 and the bill is reintroduced in the 120th Congress (2027-2029). Investors in these three names face the risk over a 12-24 month horizon.